Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ASMB
ASMB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ASMB News
Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment
Dec 22 2025
Benzinga
Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment
Dec 22 2025
NASDAQ.COM
Gilead Activates License for Assembly Biosciences' Herpes Initiatives
Dec 22 2025
SeekingAlpha
Assembly Software Reports 350% Year-over-Year Growth in NeosAI Adoption for 2025
Dec 17 2025
Globenewswire
Assembly Unveils Encouraging Initial Trial Findings for ABI-1179 and ABI-5366 in Recurrent Genital Herpes
Dec 09 2025
NASDAQ.COM
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
Assembly Bio Reports Significant Interim Results for Two HSV-2 Therapeutics
Dec 08 2025
Globenewswire
Assembly Bio Reports Significant Phase 1b Results for ABI-1179 and ABI-5366 Antiviral Candidates
Dec 08 2025
Newsfilter
Mizuho Keeps Outperform Rating for Assembly Biosciences and Increases Price Target to $40
Nov 20 2025
Benzinga
IRON Strengthens, MNMD Offers Reassurance to Investors, Could NKTR Experience an Early Christmas?
Oct 19 2025
NASDAQ.COM
Assembly Biosciences Unveils Interim Phase 1b Results for HSV Helicase-Primase Inhibitor ABI-5366 at the 38th IUSTI Europe Congress on Sexually Transmitted Infections
Oct 10 2025
Newsfilter
4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance
Sep 29 2025
Benzinga
JMP Securities Begins Coverage of Assembly Biosciences (ASMB) with a Positive Market Outlook
Sep 25 2025
NASDAQ.COM
JMP Securities Begins Coverage of Assembly Biosciences, Assigns Market Outperform Rating and Sets Price Target at $38
Sep 24 2025
Benzinga
Guggenheim Reaffirms Buy Rating on Assembly Biosciences, Increases Price Target to $39
Sep 08 2025
Benzinga
HC Wainwright & Co. Initiates Coverage on Assembly Biosciences with a Buy Rating and Sets Price Target at $50
Aug 18 2025
Benzinga
Show More News
